TGTX (STOCKS)
TG Therapeutics, Inc.
$50.300000
+0.780000 (+1.58%)
Prev close: $49.520000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Sean Weiss
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,700.13M
- Employees
- 352
- P/E (TTM)
- 17.26
- P/B (TTM)
- 13.00
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
9
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.18 | $0.30 | -0.1205 | -40.10% |
|
Dec 2025 (Q4)
|
$0.14 | $0.36 | -0.2183 | -60.93% |
|
Sep 2025 (Q3)
|
$0.16 | $0.22 | -0.0644 | -28.70% |
|
Jun 2025 (Q2)
|
$0.17 | $0.22 | -0.0515 | -23.25% |
Financial Statements
| Revenues | $700.35M |
| Benefits Costs and Expenses | $578.06M |
| Cost Of Revenue | $118.68M |
| Costs And Expenses | $550.85M |
| Gross Profit | $581.67M |
| Nonoperating Income/Loss | -$27.21M |
| Operating Expenses | $432.17M |
| Selling, General, and Administrative Expenses | $269.92M |
| Research and Development | $162.25M |
| Operating Income/Loss | $149.50M |
| Income/Loss From Continuing Operations After Tax | $461.90M |
| Income/Loss From Continuing Operations Before Tax | $122.29M |
| Income Tax Expense/Benefit | -$339.61M |
| Income Tax Expense/Benefit, Deferred | -$344.14M |
| Net Income/Loss | $461.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $461.90M |
| Net Income/Loss Available To Common Stockholders, Basic | $461.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $3.22 |
| Diluted Earnings Per Share | $2.87 |
| Basic Average Shares | 434,639,336 |
| Diluted Average Shares | 482,930,080 |
| Assets | $1.53B |
| Current Assets | $1.09B |
| Cash | $572.80M |
| Inventory | $129.03M |
| Other Current Assets | $385.14M |
| Noncurrent Assets | $441.87M |
| Liabilities | $945.71M |
| Current Liabilities | $187.11M |
| Noncurrent Liabilities | $758.60M |
| Equity | $583.13M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $583.13M |
| Liabilities And Equity | $1.53B |
| Net Cash Flow From Operating Activities | -$13.95M |
| Net Cash Flow From Operating Activities, Continuing | -$13.95M |
| Net Cash Flow From Investing Activities | $16.87M |
| Net Cash Flow From Investing Activities, Continuing | $16.87M |
| Net Cash Flow From Financing Activities | $307.20M |
| Net Cash Flow From Financing Activities, Continuing | $307.20M |
| Net Cash Flow | $310.12M |
| Net Cash Flow, Continuing | $310.12M |
| Comprehensive Income/Loss | $461.90M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $461.90M |
| Other Comprehensive Income/Loss | $0.00 |